The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Longitudinal inflammatory-metabolic-adiposity burden and incident heart failure across cardiovascular-kidney-metabolic stages: a prospective cohort study
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410027 · Cited by 1,009
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450 · cited 1×
“Central adiposity may further contribute through adipose tissue inflammation, altered adipokine secretion, ectopic fat deposition, and increased haemodynamic load [25–27].”
Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00469-0 · Cited by 386 · cited 1×
“…and glucose-lipid dysregulation may promote endothelial dysfunction, oxidative stress, neurohormonal activation, and myocardial energy metabolic impairment Individuals [22], all of which have been implicated in the progression from cardiometabolic risk to cardiac dysfunction [13, 23, 24].”
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure
Kramer, C. M., Borlaug, B. A., Zile, M. R., Ruff, D., DiMaria, J. M., Menon, V., Ou, Y., Zarante, A. M., Hurt, K. C., Murakami, M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.001 · Cited by 200
Packer, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.009 · Cited by 49
Research works printed but not linked: 35
- Heidenreich PA, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/american heart association joint committee on clinical practice guidelines. circulation. 2022;145:e895–1032.
- Ndumele CE, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American heart association. Circulation. 2023;148:1606–35. · DOI · Paper page
- Ndumele CE, et al. A Synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American heart association. Circulation. 2023;148:1636–64. · DOI · Paper page
- Li W, et al. Association between the triglyceride glucose-body mass index and future cardiovascular disease risk in a population with cardiovascular-kidney-metabolic syndrome stage 0–3: a nationwide prospective cohort study. Cardiovasc Diabetol. 2024;23:292. · DOI · Paper page
- Zhang P, Mo D, Zeng W, Dai H. Association between triglyceride-glucose related indices and all-cause and cardiovascular mortality among the population with cardiovascular-kidney-metabolic syndrome stage 0–3: a cohort study. Cardiovasc Diabetol. 2025;24:92. · DOI
- Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011–2020. JAMA. 2024;331:1858–60. · DOI · Paper page
- Xu L, et al. Triglyceride-glucose index associates with incident heart failure: a cohort study. Diabetes Metab. 2022;48:101365. · DOI
- Burger PM, et al. C-reactive protein and risk of incident heart failure in patients with cardiovascular disease. J Am Coll Cardiol. 2023;82:414–26. · DOI
- Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6:299–304. · DOI · Paper page
- Guerrero-Romero F, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95:3347–51. · DOI · Paper page
- Ren Q, et al. Association between triglyceride glucose-waist height ratio index and cardiovascular disease in middle-aged and older Chinese individuals: a nationwide cohort study. Cardiovasc Diabetol. 2024;23:247. · DOI
- Duan M, et al. Metabolic score for insulin resistance (METS-IR) predicts all-cause and cardiovascular mortality in the general population: evidence from NHANES 2001–2018. Cardiovasc Diabetol. 2024;23:243. · DOI · Paper page
- Ou H, Wei M, Li X, Xia X. C-reactive protein-triglyceride glucose index in evaluating cardiovascular disease and all-cause mortality incidence among individuals across stages 0–3 of cardiovascular-kidney-metabolic syndrome: a nationwide prospective cohort study. Cardiovasc Diabetol. 2025;24:296. · DOI
- Lu L, et al. Association between cumulative changes of the triglyceride glucose index and incidence of stroke in a population with cardiovascular-kidney-metabolic syndrome stage 0–3: a nationwide prospective cohort study. Cardiovasc Diabetol. 2025;24:202. · DOI
- Hong J, et al. Comparison of triglyceride glucose index and modified triglyceride glucose indices in predicting cardiovascular diseases incidence among populations with cardiovascular-kidney-metabolic syndrome stages 0–3: a nationwide prospective cohort study. Cardiovasc Diabetol. 2025;24:98. · DOI
- Khalaji A, et al. Triglyceride-glucose index and heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol. 2023;22:244. · DOI · Paper page
- Steptoe A, Breeze E, Banks J, Nazroo J. Cohort profile: the English longitudinal study of ageing. Int J Epidemiol. 2013;42:1640–8. · DOI · Paper page
- Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev. 2012;13:275–86. · DOI · Paper page
- Jayedi A, Soltani S, Zargar MS, Khan TA, Shab-Bidar S. Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. BMJ 2020;370:m3324. · DOI · Paper page
- Murphy SP, Kakkar R, McCarthy CP, Januzzi JL. Inflammation in heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:1324–40. · DOI · Paper page
- He H-M, et al. The synergistic effect of the triglyceride-glucose index and a body shape index on cardiovascular mortality: the construction of a novel cardiovascular risk marker. Cardiovasc Diabetol. 2025;24:69. · DOI
- Ni W, et al. Association between insulin resistance indices and outcomes in patients with heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2025;24:32. · DOI
- Luo L, Zuo Y, Dai L. Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF. Cardiovasc Diabetol. 2025;24:155. · DOI
- Delalat S, et al. Dysregulated inflammation, oxidative stress, and protein quality control in diabetic HFpEF: unraveling mechanisms and therapeutic targets. Cardiovasc Diabetol. 2025;24:211. · DOI
- Lakhani I, et al. Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart Fail Rev. 2021;26:1141–50. · DOI
- Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71. · DOI · Paper page
- Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021;18:400–23. · DOI · Paper page
- Kosiborod MN, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390:1394–407. · DOI · Paper page
- Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109–38. · DOI · Paper page
- Borlaug BA, et al. Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF: the SUMMIT trial. J Am Coll Cardiol. 2025;86:242–55. · DOI
- Gauthier J, Wu QV, Gooley TA. Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transpl. 2020;55:675–80. · DOI · Paper page
- Discacciati A, et al. Estimating and presenting non-linear associations with restricted cubic splines. Int J Epidemiol. 2025;54:dyaf088. · DOI
- Tsai M-K, et al. Cardiovascular-kidney-metabolic syndrome and all-cause and cardiovascular mortality: a retrospective cohort study. PLoS Med. 2025;22:e1004629. · DOI
- van Dalen BM, et al. Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity. Cardiovasc Diabetol. 2025;24:71. · DOI
- Bozkurt B, et al. Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure: endorsed by the Canadian heart failure society, heart failure association of India, cardiac society of Australia and New Zealand, and Chinese heart failure association. Eur J Heart Fail. 2021;23:352–80. · DOI · Paper page
Metadata
- Authors
- Dai, F., & Dai, Y.
- Venue
- Cardiovascular Diabetology
- Published
- 2026-07-26
- Volume
- 25
- Issue
- 1
- ISSN
- 1475-2840
- Cited by
- 0
- References
- 5
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor, 39 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Longitudinal inflammatory-metabolic-adiposity burden and incident heart failure across cardiovascular-kidney-metabolic stages: a prospective cohort study. https://app.cochat.ai/papers/10.1186/s12933-026-03310-0
- The paper
- Dai, F., & Dai, Y. (2026). Longitudinal inflammatory-metabolic-adiposity burden and incident heart failure across cardiovascular-kidney-metabolic stages: a prospective cohort study. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-026-03310-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.